

*Journal of Organometallic Chemistry*, 412 (1991) 47–52  
Elsevier Sequoia S.A., Lausanne  
JOM 21794

## Stereoselective addition of allylstibonium bromide to aldehydes \*

Yao-Zeng Huang \*, Li-Jun Zhang, Chen Chen and Guang-Zhong Guo

*Laboratory of Organometallic Chemistry, Shanghai Institute of Organic Chemistry, Academia Sinica, 345 Lingling Lu, Shanghai 200032 (People's Republic of China)*

(Received December 21st, 1990)

### Abstract

Reaction of allylantimony with aldehydes provides homoallylic alcohols with high *threo* selectivity in the case of (*E*)-4-methyl-2-pentenylantimony (**2c**) and with preferential *erythro* selectivity in the case of crotylantimony (**2a**).

### Introduction

Stereoselective synthesis of  $\alpha$ -methylhomoallylic alcohols, of possible application to the synthesis of macrolide and polyether antibiotics and of some pheromones, is one of the most challenging problems for the synthetic chemist [1]. One successful strategy for this purpose involves stereoselective reaction of crotylmetals with aldehydes [2]. Of particular interest is the dependence of the stereoselectivity of crotylstannanes upon the reaction conditions [3]. However, the analogous reaction of allylantimony has hardly been studied [4]. Here we report a diastereoselective addition of allylantimony to aldehydes.

### Results and discussion

Allylantimony **2** was readily obtained by mixing tributylstibine with bromides **1** at room temperature. Heating the salt **2** with a variety of aldehydes under nitrogen produced homoallylic alcohols **3** in high yield. This reaction was performed without any solvent. The reaction can also take place in 1,4-dioxane under reflux with moderate yield and similar diastereoselectivity. However, the reaction was slow in THF under reflux, because of the low boiling point of THF. The ratio of *threo* and *erythro* was determined by <sup>1</sup>H NMR and/or capillary GC analysis by comparison with authentic samples. The results are summarized in Table 1.

\* This paper is the XCIII report on the studies of the application of elemento-organic compounds of the 15th and 16th groups in organic synthesis.



The diastereoselectivity of this reaction depends greatly upon the substituent R. In the case of **2a** (R = CH<sub>3</sub>), a mixture of *erythro* and *threo* isomers was isolated in a ratio of about 2:1 (entries a–g). In the case of the highly hindered **2c** (R = (CH<sub>3</sub>)<sub>2</sub>CH), the *threo* isomer was obtained with 70–98% diastereoselectivity (entries l–o).

As a result of the enhanced ionic nature of the Br–Sb bond, either the cyclic or acyclic transition state in this reaction could be favoured. In the case of **2a**, stibonium bromide may act as a Lewis acid, and the propensity to an acyclic transition state seems to be greater than that to a cyclic transition state, consequently erythroselectivity was observed. Otherwise, in the case of **2c**, because of the steric properties of iso-propyl the propensity to a cyclic transition state was greater, so a high degree of *threo*-selectivity was observed as in the case of crotyltins [2]. As for **2b**, the result was intermediate. However, this mechanistic rationale is speculative. Confirmation of the mechanism of this reaction awaits more detailed understanding of the reaction course.

## Experimental

IR spectra were obtained on a Shimadzu IR-440 spectrophotometer and are reported in cm<sup>-1</sup> units (neat). Mass spectra were measured on a Finnigan GC-MC 4021 spectrometer. <sup>1</sup>H NMR spectra were recorded on a Varian EM-360 or AM-500 spectrometer in CCl<sub>4</sub> solution unless noted otherwise, with TMS as an internal standard and are reported in δ units (ppm).

### 2-Methyl-1-phenyl-3-buten-1-ol (**3a** entry a) [3b]

Typical procedure: Tributylstibine (675 mg, 2.3 mmol) and crotyl bromide (350 mg, 2.6 mmol) were mixed and stirred at ambient temperature for 8 h under nitrogen. The resulting oily product was heated with benzaldehyde (210 mg, 2.0 mmol) at 100 °C for 15–18 h. After protonolysis with wet alcohol, the mixture was chromatographed on an alumina–silica gel (1:1) column, eluting with 95:5 petroleum ether/ethyl acetate to give a mixture of α- and γ-adduct products (310 mg, 97%), b.p. 93–95 °C/1 mmHg. *threo*-Form. <sup>1</sup>H NMR: 0.88 (d, *J*<sub>1</sub> = 7.0 Hz, 3H); 1.70 (brs, 1H); 2.42 (m, 1H); 4.31 (d, *J*<sub>2</sub> = 7.0 Hz, 1H); 4.70–5.26 (m, 2H); 5.30–6.10 (m, 1H); 7.26 (s, 5H). IR: 3400, 1640, 1270, 1020, 980, 910, 760, 700 cm<sup>-1</sup>. MS: 162 (*M*<sup>+</sup>, 0.1), 145 (26), 108 (100), 107 (28), 105 (23), 80 (42), 79 (35), 77 (53). *erythro*-Form. <sup>1</sup>H NMR: 0.95 (d, *J*<sub>1</sub> = 7.0 Hz, 3H); 4.50 (d, *J*<sub>3</sub> = 6 Hz, 1H). The other data of <sup>1</sup>H NMR, IR and MS are the same as above.

### 1-(4-Bromophenyl)-2-methyl-3-buten-1-ol (**3a** entry b)

From 4-bromobenzaldehyde: 370 mg. Mixture products: 450 mg, 93%. B.p. 138–140 °C/1 mmHg. *threo*-Form. <sup>1</sup>H NMR: 0.83 (d, *J*<sub>1</sub> = 7.0 Hz, 3H); 2.20 (brs, 1H); 2.35 (m, 1H); 4.20 (d, *J*<sub>2</sub> = 7.0 Hz, 1H); 4.70–5.20 (m, 2H); 5.60 (m, 1H); 7.06 (d, *J*<sub>3</sub> = 10.0 Hz, 2H); 7.39 (d, *J*<sub>3</sub> = 10.0 Hz, 2H). IR: 3400, 1640, 1010, 920 cm<sup>-1</sup>. MS: 242, 240 (*M*<sup>+</sup>, 0.1), 225, 223 (14), 187 (84), 157 (19), 77 (100). *erythro*-Form. <sup>1</sup>H NMR: 0.92 (d, *J*<sub>1</sub> = 7.0 Hz, 3H); 4.37 (d, *J*<sub>4</sub> = 5.5 Hz, 1H). The other data of <sup>1</sup>H NMR, IR and MS are the same as above. Anal. Found: C, 54.57; H, 5.57. C<sub>11</sub>H<sub>13</sub>BrO (mixture products) calcd.: C, 54.79; H, 5.43%.

*2-Methyl-1-p-tolyl-3-buten-1-ol (3a entry c) [3b]*

From *p*-tolualdehyde: 240 mg. Mixture products: 325 mg, 92%. B.p. 114–117°C/1 mmHg. *threo*-form. <sup>1</sup>H NMR: 0.85 (d,  $J_1 = 6.5$  Hz, 3H); 1.25–2.25 (m, 2H); 2.32 (s, 3H); 4.22 (d,  $J_2 = 7.0$  Hz, 1H); 4.95–5.15 (m, 2H); 5.48–5.80 (m, 1H); 7.08 (bs, 4H). IR: 3610, 1620, 1050, 990, 910  $\text{cm}^{-1}$ . MS: 176 ( $M^+$ , 0.2), 175 (0.4), 159 (14), 122 (100), 93 (59), 91 (40), 77 (30). *erythro*-Form. <sup>1</sup>H NMR: 0.95 (d,  $J_1 = 6.5$  Hz, 3H); 4.40 (d,  $J_3 = 6.0$  Hz, 1H). The other data of <sup>1</sup>H NMR, IR and MS are the same as above.

*1-(4-Chlorophenyl)-2-methyl-3-buten-1-ol (3a entry d) [3a]*

From 4-chlorobenzaldehyde: 281 mg. Mixture products: 360 mg, 92%. *threo*-Form. <sup>1</sup>H NMR ( $\text{CDCl}_3$ ): 0.87 (d,  $J_1 = 7.0$  Hz, 3H); 2.30 (m, 1H); 2.35 (brs, 1H); 4.35 (d,  $J_2 = 6.8$  Hz, 1H); 4.80–5.25 (m, 2H); 5.40–6.10 (m, 1H); 7.20 (s, 4H). IR: 3400, 1640, 1095, 1010, 990, 920  $\text{cm}^{-1}$ . MS: 196 ( $M^+$ , 0.2), 181 (6), 179 (18), 143 (41), 142 (55), 141 (100), 113 (27), 77 (88). *erythro*-Form. <sup>1</sup>H NMR: 0.98 (d,  $J_1 = 7.0$  Hz, 3H); 4.60 (d,  $J_3 = 5.6$  Hz, 1H). The other data of <sup>1</sup>H NMR, IR and MS are the same as above.

*2,4-Dimethyl-5-hexen-3-ol (3a entry e) [3b]*

From isobutyraldehyde: 144 mg. Mixture products: 230 mg, 90%. *threo*-Form. <sup>1</sup>H NMR: 0.8–1.1 (m, 9H); 1.4 (m, 1H); 1.64 (brs, 1H); 2.06 (m, 1H); 3.00 (dd,  $J_1 = 5.0$ ,  $J_2 = 10.5$  Hz, 1H); 4.75–5.16 (m, 2H); 5.68 (m, 1H). IR: 3400, 1630, 1000, 910  $\text{cm}^{-1}$ . MS: 128 ( $M^+$ , 0.3), 111 (9), 73 (57), 56 (100). *erythro*-Form. The same <sup>1</sup>H NMR, IR and MS spectra as above.

*3-Methyl-1,5-heptadien-4-ol (3a entry f) [3b]*

From crotonaldehyde: 140 mg. Mixture products: 230 mg, 92%. *threo*-Form. <sup>1</sup>H NMR: 0.97 (d,  $J_1 = 6.6$  Hz, 3H); 1.70 (d,  $J_2 = 5.0$  Hz, 3H); 2.25 (m, 1H); 2.7 (bs, 1H); 3.8 (dd,  $J_3 = 5.5$ ,  $J_4 = 10.0$  Hz, 1H); 4.85–5.05 (m, 2H); 5.40–5.90 (m, 3H). IR: 3600, 1640, 990, 960, 910  $\text{cm}^{-1}$ . MS: 126 ( $M^+$ , 0.2), 125 (1), 109 (46), 72 (100), 69 (23), 43 (58). *erythro*-Form. The same <sup>1</sup>H NMR, IR and MS spectra as above.

*3-Methyl-1-dodecen-4-ol (3a entry g) [6]*

From nonyl aldehyde: 284 mg. Mixture products: 375 mg, 95%. *threo*-Form. <sup>1</sup>H NMR: 0.85 (m, 6H); 1.15 (brs, 12H); 1.33 (brs, 1H); 1.53 (m, 2H); 2.0 (m, 1H); 3.20 (m, 1H); 4.65–5.05 (m, 2H); 5.55 (m, 1H). IR: 3400, 1640, 990, 910  $\text{cm}^{-1}$ . MS: 198 ( $M^+$ , 0.4), 181 (0.5), 143 (11), 141 (14), 83 (48), 71 (23), 69 (79), 56 (100). *erythro*-Form. The same <sup>1</sup>H NMR, IR and MS spectra as above.

*1-(4-Chlorophenyl)-2-propyl-3-buten-1-ol (3b entry h)*

From 4-chlorobenzaldehyde: 281 mg. Mixture products: 425 mg, 95%. B.p. 140–145°C/1 mmHg. *threo*-Form. <sup>1</sup>H NMR ( $\text{CDCl}_3$ ): 0.78 (t,  $J_1 = 7.0$  Hz, 3H); 1.13–1.48 (m, 4H); 2.10 (brs, 1H); 2.23 (m, 1H); 4.40 (d,  $J_2 = 6.8$  Hz, 1H); 5.15–5.26 (m, 2H); 5.58–6.68 (m, 1H); 7.25 (m, 4H). IR: 3400, 1640, 1090, 1020, 920, 830  $\text{cm}^{-1}$ . MS: 224 ( $M^+$ , 0.14), 207 (4), 143 (53), 141 (100), 113 (12), 77 (51). *erythro*-Form. <sup>1</sup>H NMR: 0.86 (t,  $J_1 = 7.0$  Hz, 3H); 2.38 (m, 1H); 4.60 (d,  $J_3 = 5.8$  Hz, 1H); 4.98–5.08 (m, 2H); 5.43–5.50 (m, 1H). The other data of <sup>1</sup>H NMR, IR and MS are the same as above.

**2-Propyl-1-p-tolyl-3-buten-1-ol (3b entry i)**

From *p*-tolualdehyde: 240 mg. Mixture products: 385 mg, 95%. B.p. 130–133°C/1 mmHg. *threo*-Form. <sup>1</sup>H NMR: 0.9 (t,  $J_1 = 7.0$  Hz, 3H); 1.0–1.5 (m, 4H); 2.0 (brs, 1H); 2.20 (m, 1H); 2.30 (s, 3H); 4.25 (d,  $J_2 = 7.8$ , 1H); 4.8–5.2 (m, 2H); 5.3–5.9 (m, 1H); 7.05 (s, 4H). IR: 3400, 1640, 1030, 1000, 915, 820 cm<sup>-1</sup>. MS: 204 ( $M^+$ , 3.7), 187 (9), 162 (56), 121 (7), 91 (100). *erythro*-Form. <sup>1</sup>H NMR: 4.36 (d,  $J_3 = 6.0$  Hz, 1H). The other data of <sup>1</sup>H NMR, IR and MS are the same as above. Anal. Found: C, 82.47; H, 10.06. C<sub>14</sub>H<sub>20</sub>O (mixture products) calcd.: C, 82.30; H, 9.87%.

**2-Methyl-4-propyl-5-hexen-3-ol (3b entry j)**

From isobutyraldehyde: 144 mg. Mixture products: 285 mg, 91%. B.p. 80–83°C/12 mmHg. *threo*-Form. <sup>1</sup>H NMR: 0.9–1.2 (m, 9H); 1.2–1.8 (m, 5H); 1.8–2.5 (m, 2H); 3.05–3.55 (m, 1H); 4.90–5.40 (m, 2H); 5.5–6.0 (m, 1H). IR: 3400, 1640, 1000, 910 cm<sup>-1</sup>. MS: 156 ( $M^+$ , 0.5), 139 (7), 84 (77), 73 (44), 69 (30), 56 (100). *erythro*-Form. The same <sup>1</sup>H NMR, IR and MS spectra as above.

**3-Propyl-1,5-heptadien-4-ol (3b entry k)**

From crotonaldehyde: 140 mg. Mixture products: 285 mg, 93%. B.p. 96–100°C/15 mmHg. *threo*-Form. <sup>1</sup>H NMR: 0.9 (t,  $J = 7.0$  Hz, 3H); 1.0–1.5 (m, 4H); 1.5–2.5 (m, 5H); 3.7–4.0 (m, 1H); 4.7–5.9 (m, 5H). IR: 3400, 1640, 1020, 970, 910 cm<sup>-1</sup>. MS: 154 ( $M^+$ , 0.14), 138 (100), 136 (5), 95 (30), 81 (47), 71 (85). *erythro*-Form. The same <sup>1</sup>H NMR, IR and MS spectra as above.

**1-(4-Chlorophenyl)-2-iso-propyl-3-buten-1-ol (3c entry l)**

From 4-chlorobenzaldehyde: 281 mg. Mixture products: 420 mg, 94%. B.p. 138–142°C/1 mmHg. *threo*-Form. <sup>1</sup>H NMR: 0.85–1.15 (m, 6H); 1.60 (m, 1H); 2.05 (brs, 1H); 2.40 (m, 1H); 4.65 (d,  $J_1 = 7.5$  Hz, 1H); 5.1–6.1 (m, 3H); 7.3 (s, 4H). IR: 3450, 1640, 1090, 1020, 920, 820 cm<sup>-1</sup>. MS: 224 ( $M^+$ , 0.5), 207 (13), 182 (35), 121 (89), 91 (100). *erythro*-Form. The same <sup>1</sup>H NMR, IR and MS spectra as above.

**1-(4-Methylphenyl)-2-isopropyl-3-buten-1-ol (3c entry m)**

From *p*-tolualdehyde: 240 mg. Mixture products: 385 mg, 95%. B.p. 127–130°C/1 mmHg. *threo*-Form. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 0.827 (d,  $J_1 = 6.8$  Hz, 6H); 1.46 (m, 1H); 1.95 (brs, 1H); 2.15 (m, 1H); 2.35 (s, 3H); 4.56 (d,  $J_2 = 8.6$  Hz, 1H); 5.15–5.29 (m, 2H); 5.80 (m, 1H); 7.23 (m, 4H). IR: 3400, 1640, 1040, 1000, 910, 810 cm<sup>-1</sup>. MS: 204 ( $M^+$ , 0.1), 203 (0.5), 187 (42), 131 (19), 122 (100), 105 (20). *erythro*-Form. <sup>1</sup>H NMR: 0.90 (d,  $J_1 = 6.8$  Hz, 6H); 2.22 (m, 1H); 4.68 (d,  $J_3 = 8.0$  Hz, 1H); 4.85–4.98 (m, 2H); 5.36 (m, 1H). The other data of <sup>1</sup>H NMR, IR and MS are the same as above.

**2-Methyl-4-isopropyl-5-hexen-3-ol (3c entry n)**

From isobutyraldehyde: 144 mg. Mixture products: 295 mg, 95%. B.p. 78–82°C/12 mmHg. *threo*-Form. <sup>1</sup>H NMR: 0.80–1.0 (m, 12H); 1.2–1.5 (m, 2H); 1.9–2.4 (m, 2H); 3.0–3.3 (m, 1H); 4.9–6.0 (m, 3H). IR: 3400, 1640, 1010, 910 cm<sup>-1</sup>. MS: 156 ( $M^+$ , 0.1), 113 (2), 84 (69), 73 (52), 69 (100), 55 (56), 43 (73), 41 (53). *erythro*-Form. The same <sup>1</sup>H NMR, IR and MS spectra as above. Anal. Found: C, 76.82; H, 13.34. C<sub>10</sub>H<sub>20</sub>O (mixture products) calcd.: C, 76.80; H, 12.90%.

*3-Isopropyl-1,5-heptadien-4-ol (3c entry o)*

From crotonaldehyde: 140 mg. Mixture products: 285 mg, 93%. B.p. 95–98 °C/15 mmHg. *threo*-Form.  $^1\text{H}$  NMR: 0.9–1.6 (m, 7H); 1.7–2.4 (m, 5H); 4.0–4.4 (m, 1H); 5.10–6.20 (m, 3H). IR: 3400, 1640, 1020, 910  $\text{cm}^{-1}$ . MS: 154 ( $M^+$ , 0.2), 153 (2), 138 (100), 136 (5), 95 (18), 81 (44), 71 (41). *erythro*-Form. The same  $^1\text{H}$  NMR, IR and MS spectra as above. Anal. Found: C, 77.71; H, 11.73.  $\text{C}_{10}\text{H}_{18}\text{O}$  (mixture products) calcd.: C, 77.87; H, 11.76%.

**Acknowledgements**

Thanks are due to the National Natural Science Foundation of China and Academia Sinica for financial support. Thanks are also due to Professor Xiao-Tian Liang for his valuable discussion.

**References and notes**

- 1 P.A. Bartlett, *Tetrahedron*, 36 (1980) 3.
- 2 R.W. Hoffmann, *Angew. Chem., Int. Ed. Engl.*, 21 (1982) 555.
- 3 (a) C. Servens and M. Pereyre, *J. Organomet. Chem.*, 35 (1972) C20; (b) Y. Yamamoto, H. Yatagai, Y. Ishihara, N. Maeda and K. Maruyama, *Tetrahedron*, 40 (1984) 2239.
- 4 (a) Y. Butsugan, H. Ito and S. Araki, *Tetrahedron Lett.*, 28 (1987) 3707; (b) C. Chen, Y.-Z. Huang and Y.C. Shen, *Tetrahedron Lett.*, 29 (1988) 1395.
- 5 The reaction of crotyltin with aldehyde results in  $\alpha$ -adducts as by-products in the presence of  $\text{BF}_3 \cdot \text{Et}_2\text{O}$  and as major products in the presence of  $\text{AlCl}_3 \cdot \text{PrOH}$ . The formation of  $\alpha$ -adducts was due to trans-metallation via a  $S_{\text{E}}2'$  process followed by a rapid reaction with aldehydes. Y. Yamamoto and K. Maruyama, *J. Organomet. Chem.*, 284 (1985) C45.
- 6 M. Kiva, M. Kobayashi and H. Sakurai, *Tetrahedron Lett.*, 28 (1987) 4081.